Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
29
BIB Quote, Financials, Valuation and Earnings
Last price:
$51.50
Seasonality move
:
5.96%
Day range:
$49.49 - $52.41
52-week range:
$47.20 - $69.56
Dividend yield:
0.97%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
7K
Avg. volume:
13.8K
1-year change:
0.71%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BIB
ProShares Ultra Nasdaq Biotechnology
|
-- | -- | -- | -- | -- |
|
DRN
Direxion Daily Real Estate Bull 3X Shares
|
-- | -- | -- | -- | -- |
|
HIBL
Direxion Daily S&P 500 High Beta Bull 3X Shares
|
-- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
NUGT
Direxion Daily Gold Miners Index Bull 2X Shares
|
-- | -- | -- | -- | -- |
|
URE
ProShares Ultra Real Estate
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BIB
ProShares Ultra Nasdaq Biotechnology
|
$51.41 | -- | -- | -- | $0.15 | 0.97% | -- |
|
DRN
Direxion Daily Real Estate Bull 3X Shares
|
$9.71 | -- | -- | -- | $0.06 | 2.54% | -- |
|
HIBL
Direxion Daily S&P 500 High Beta Bull 3X Shares
|
$43.99 | -- | -- | -- | $0.07 | 1.04% | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
$21.60 | -- | -- | -- | $0.09 | 1.09% | -- |
|
NUGT
Direxion Daily Gold Miners Index Bull 2X Shares
|
$36.32 | -- | -- | -- | $0.07 | 1.96% | -- |
|
URE
ProShares Ultra Real Estate
|
$62.13 | -- | -- | -- | $0.32 | 2.16% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BIB
ProShares Ultra Nasdaq Biotechnology
|
-- | 1.943 | -- | -- |
|
DRN
Direxion Daily Real Estate Bull 3X Shares
|
-- | 3.745 | -- | -- |
|
HIBL
Direxion Daily S&P 500 High Beta Bull 3X Shares
|
-- | 4.284 | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | 1.252 | -- | -- |
|
NUGT
Direxion Daily Gold Miners Index Bull 2X Shares
|
-- | -1.223 | -- | -- |
|
URE
ProShares Ultra Real Estate
|
-- | 2.565 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BIB
ProShares Ultra Nasdaq Biotechnology
|
-- | -- | -- | -- | -- | -- |
|
DRN
Direxion Daily Real Estate Bull 3X Shares
|
-- | -- | -- | -- | -- | -- |
|
HIBL
Direxion Daily S&P 500 High Beta Bull 3X Shares
|
-- | -- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
NUGT
Direxion Daily Gold Miners Index Bull 2X Shares
|
-- | -- | -- | -- | -- | -- |
|
URE
ProShares Ultra Real Estate
|
-- | -- | -- | -- | -- | -- |
ProShares Ultra Nasdaq Biotechnology vs. Competitors
-
Which has Higher Returns BIB or DRN?
Direxion Daily Real Estate Bull 3X Shares has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat Direxion Daily Real Estate Bull 3X Shares's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BIBProShares Ultra Nasdaq Biotechnology-- -- -- DRNDirexion Daily Real Estate Bull 3X Shares-- -- -- -
What do Analysts Say About BIB or DRN?
ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand Direxion Daily Real Estate Bull 3X Shares has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than Direxion Daily Real Estate Bull 3X Shares, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than Direxion Daily Real Estate Bull 3X Shares.
Company Buy Ratings Hold Ratings Sell Ratings BIBProShares Ultra Nasdaq Biotechnology0 0 0 DRNDirexion Daily Real Estate Bull 3X Shares0 0 0 -
Is BIB or DRN More Risky?
ProShares Ultra Nasdaq Biotechnology has a beta of 1.340, which suggesting that the stock is 34.013% more volatile than S&P 500. In comparison Direxion Daily Real Estate Bull 3X Shares has a beta of 3.083, suggesting its more volatile than the S&P 500 by 208.333%.
-
Which is a Better Dividend Stock BIB or DRN?
ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.15 per share corresponding to a yield of 0.97%. Direxion Daily Real Estate Bull 3X Shares offers a yield of 2.54% to investors and pays a quarterly dividend of $0.06 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. Direxion Daily Real Estate Bull 3X Shares pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIB or DRN?
ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than Direxion Daily Real Estate Bull 3X Shares quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than Direxion Daily Real Estate Bull 3X Shares's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while Direxion Daily Real Estate Bull 3X Shares's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for Direxion Daily Real Estate Bull 3X Shares. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIBProShares Ultra Nasdaq Biotechnology-- -- -- -- DRNDirexion Daily Real Estate Bull 3X Shares-- -- -- --
-
Which has Higher Returns BIB or HIBL?
Direxion Daily S&P 500 High Beta Bull 3X Shares has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat Direxion Daily S&P 500 High Beta Bull 3X Shares's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BIBProShares Ultra Nasdaq Biotechnology-- -- -- HIBLDirexion Daily S&P 500 High Beta Bull 3X Shares-- -- -- -
What do Analysts Say About BIB or HIBL?
ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand Direxion Daily S&P 500 High Beta Bull 3X Shares has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than Direxion Daily S&P 500 High Beta Bull 3X Shares, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than Direxion Daily S&P 500 High Beta Bull 3X Shares.
Company Buy Ratings Hold Ratings Sell Ratings BIBProShares Ultra Nasdaq Biotechnology0 0 0 HIBLDirexion Daily S&P 500 High Beta Bull 3X Shares0 0 0 -
Is BIB or HIBL More Risky?
ProShares Ultra Nasdaq Biotechnology has a beta of 1.340, which suggesting that the stock is 34.013% more volatile than S&P 500. In comparison Direxion Daily S&P 500 High Beta Bull 3X Shares has a beta of 4.409, suggesting its more volatile than the S&P 500 by 340.897%.
-
Which is a Better Dividend Stock BIB or HIBL?
ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.15 per share corresponding to a yield of 0.97%. Direxion Daily S&P 500 High Beta Bull 3X Shares offers a yield of 1.04% to investors and pays a quarterly dividend of $0.07 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. Direxion Daily S&P 500 High Beta Bull 3X Shares pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIB or HIBL?
ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than Direxion Daily S&P 500 High Beta Bull 3X Shares quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than Direxion Daily S&P 500 High Beta Bull 3X Shares's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while Direxion Daily S&P 500 High Beta Bull 3X Shares's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for Direxion Daily S&P 500 High Beta Bull 3X Shares. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIBProShares Ultra Nasdaq Biotechnology-- -- -- -- HIBLDirexion Daily S&P 500 High Beta Bull 3X Shares-- -- -- --
-
Which has Higher Returns BIB or IBBQ?
Invesco Nasdaq Biotechnology ETF has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat Invesco Nasdaq Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BIBProShares Ultra Nasdaq Biotechnology-- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- -
What do Analysts Say About BIB or IBBQ?
ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Nasdaq Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than Invesco Nasdaq Biotechnology ETF, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than Invesco Nasdaq Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings BIBProShares Ultra Nasdaq Biotechnology0 0 0 IBBQInvesco Nasdaq Biotechnology ETF0 0 0 -
Is BIB or IBBQ More Risky?
ProShares Ultra Nasdaq Biotechnology has a beta of 1.340, which suggesting that the stock is 34.013% more volatile than S&P 500. In comparison Invesco Nasdaq Biotechnology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BIB or IBBQ?
ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.15 per share corresponding to a yield of 0.97%. Invesco Nasdaq Biotechnology ETF offers a yield of 1.09% to investors and pays a quarterly dividend of $0.09 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. Invesco Nasdaq Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIB or IBBQ?
ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than Invesco Nasdaq Biotechnology ETF quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than Invesco Nasdaq Biotechnology ETF's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while Invesco Nasdaq Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for Invesco Nasdaq Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIBProShares Ultra Nasdaq Biotechnology-- -- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- --
-
Which has Higher Returns BIB or NUGT?
Direxion Daily Gold Miners Index Bull 2X Shares has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat Direxion Daily Gold Miners Index Bull 2X Shares's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BIBProShares Ultra Nasdaq Biotechnology-- -- -- NUGTDirexion Daily Gold Miners Index Bull 2X Shares-- -- -- -
What do Analysts Say About BIB or NUGT?
ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand Direxion Daily Gold Miners Index Bull 2X Shares has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than Direxion Daily Gold Miners Index Bull 2X Shares, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than Direxion Daily Gold Miners Index Bull 2X Shares.
Company Buy Ratings Hold Ratings Sell Ratings BIBProShares Ultra Nasdaq Biotechnology0 0 0 NUGTDirexion Daily Gold Miners Index Bull 2X Shares0 0 0 -
Is BIB or NUGT More Risky?
ProShares Ultra Nasdaq Biotechnology has a beta of 1.340, which suggesting that the stock is 34.013% more volatile than S&P 500. In comparison Direxion Daily Gold Miners Index Bull 2X Shares has a beta of 2.359, suggesting its more volatile than the S&P 500 by 135.859%.
-
Which is a Better Dividend Stock BIB or NUGT?
ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.15 per share corresponding to a yield of 0.97%. Direxion Daily Gold Miners Index Bull 2X Shares offers a yield of 1.96% to investors and pays a quarterly dividend of $0.07 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. Direxion Daily Gold Miners Index Bull 2X Shares pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIB or NUGT?
ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than Direxion Daily Gold Miners Index Bull 2X Shares quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than Direxion Daily Gold Miners Index Bull 2X Shares's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while Direxion Daily Gold Miners Index Bull 2X Shares's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for Direxion Daily Gold Miners Index Bull 2X Shares. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIBProShares Ultra Nasdaq Biotechnology-- -- -- -- NUGTDirexion Daily Gold Miners Index Bull 2X Shares-- -- -- --
-
Which has Higher Returns BIB or URE?
ProShares Ultra Real Estate has a net margin of -- compared to ProShares Ultra Nasdaq Biotechnology's net margin of --. ProShares Ultra Nasdaq Biotechnology's return on equity of -- beat ProShares Ultra Real Estate's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BIBProShares Ultra Nasdaq Biotechnology-- -- -- UREProShares Ultra Real Estate-- -- -- -
What do Analysts Say About BIB or URE?
ProShares Ultra Nasdaq Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand ProShares Ultra Real Estate has an analysts' consensus of -- which suggests that it could fall by --. Given that ProShares Ultra Nasdaq Biotechnology has higher upside potential than ProShares Ultra Real Estate, analysts believe ProShares Ultra Nasdaq Biotechnology is more attractive than ProShares Ultra Real Estate.
Company Buy Ratings Hold Ratings Sell Ratings BIBProShares Ultra Nasdaq Biotechnology0 0 0 UREProShares Ultra Real Estate0 0 0 -
Is BIB or URE More Risky?
ProShares Ultra Nasdaq Biotechnology has a beta of 1.340, which suggesting that the stock is 34.013% more volatile than S&P 500. In comparison ProShares Ultra Real Estate has a beta of 2.071, suggesting its more volatile than the S&P 500 by 107.106%.
-
Which is a Better Dividend Stock BIB or URE?
ProShares Ultra Nasdaq Biotechnology has a quarterly dividend of $0.15 per share corresponding to a yield of 0.97%. ProShares Ultra Real Estate offers a yield of 2.16% to investors and pays a quarterly dividend of $0.32 per share. ProShares Ultra Nasdaq Biotechnology pays -- of its earnings as a dividend. ProShares Ultra Real Estate pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIB or URE?
ProShares Ultra Nasdaq Biotechnology quarterly revenues are --, which are smaller than ProShares Ultra Real Estate quarterly revenues of --. ProShares Ultra Nasdaq Biotechnology's net income of -- is lower than ProShares Ultra Real Estate's net income of --. Notably, ProShares Ultra Nasdaq Biotechnology's price-to-earnings ratio is -- while ProShares Ultra Real Estate's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProShares Ultra Nasdaq Biotechnology is -- versus -- for ProShares Ultra Real Estate. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIBProShares Ultra Nasdaq Biotechnology-- -- -- -- UREProShares Ultra Real Estate-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
